Ambiguity Aversion: Daniel Ellsberg’s 1961 Paradox and Why Indian Investors Prefer the Illusion of Probabilistic Certainty in Weekly Options Over the Honest Uncertainty of Long-Term Equity

One paragraph summary. Daniel Ellsberg published a four-page paradox in 1961 that did to Leonard Savage’s expected-utility theory what Kahneman and Tversky would later do to rational-choice theory. Given a choice between an urn whose composition is known and one whose composition is unknown — even when the expected payoffs are mathematically identical — the majority of human beings reach for the known urn. They are not avoiding risk (probability is identical). They are avoiding ambiguity — the variance over the probabilities themselves. This single insight, refined across six decades of academic literature, explains an enormous swathe of Indian retail-investor behaviour: why ₹1.81 lakh crore was lost in F&O segment trading (SEBI 2024), why median equity holding periods in India remain stubbornly under five months, why retail systematic investment plans abandon at month 21, and why portfolios stay clustered in a handful of largecap names rather than spread across a meaningful long-term opportunity set. The cure is not to suppress the discomfort of not-knowing — it is to insist on companies whose disclosure architecture compresses ambiguity to manageable size. Titan Biotech Ltd (BSE: 524717), FY25 audited, is used in this post as a positive illustrative case of corporate ambiguity-collapse. This is educational; no buy/sell/hold call is being made on any security named.

1. The Paradox: What Ellsberg Actually Showed in 1961

Daniel Ellsberg — later more famous for the Pentagon Papers, but in his Harvard PhD work a serious decision theorist — presented a deceptively simple thought experiment in the Quarterly Journal of Economics, 1961, “Risk, Ambiguity, and the Savage Axioms.” Imagine two urns. Urn A contains 50 red and 50 black balls. Urn B contains 100 balls of an unknown red/black ratio — could be 1 red and 99 black, could be 99 red and 1 black, could be anything in between. You will be paid ₹1,000 if you draw red. Which urn do you pick?

Then the same question for black. Which urn do you pick?

Under Savage’s axioms of rational choice, the answer is straightforward: it should not matter. If you preferred Urn A for red, you implicitly believe Urn B has fewer than 50 red, which means it has more than 50 black, which means you should prefer Urn B for black. But humans — reliably, across cultures, across income groups — pick Urn A in BOTH cases. They prefer known probabilities to unknown probabilities, even when the act of being consistent across both bets requires them to flip.

Ellsberg christened this ambiguity aversion. The discomfort is not about losing money (the expected value of both urns is identical). It is about the absence of a probability distribution one can plant a flag on. The classical economist’s utility function only takes payoffs and probabilities as inputs — but the human nervous system, it turns out, also takes variance over the probabilities as an input, and assigns negative utility to it.

2. The Underlying Psychology — Why Ambiguity Hurts More Than Risk

Risk and ambiguity feel similar from the outside, but inside the brain they are processed differently. Camerer and Weber (1992) reviewed two decades of follow-up work and reported that the “ambiguity premium” — the amount of expected value a person is willing to sacrifice to switch from an ambiguous bet to an equivalently-priced risky one — is roughly 10–20% on average. Hsu, Bhatt, Adolphs, Tranel and Camerer’s 2005 fMRI work, published in Science, showed that ambiguity preferentially activates the amygdala and the orbitofrontal cortex — the brain regions associated with the threat-detection response — while pure risk activates the striatum, the reward-processing region. We do not fear ambiguity the way we fear risk; we fear it the way we fear an unknown noise in the dark.

This has three downstream consequences relevant to investing:

(i) Probability-grounded options trades feel safer than equities. An option pricing model (Black-Scholes) outputs a specific probability that an option will be in-the-money. The number feels precise. The fact that the model’s implied probability is itself the output of estimates layered on estimates — volatility, drift, discount rate — is ignored. The illusion of a known probability is irresistible.

(ii) Diversification feels like surrender. Spreading capital across multiple stocks, sectors, and geographies feels like an admission that one cannot pick the winner. The ambiguity-averse mind would rather concentrate in a few names whose stories it understands than diversify across many whose probabilities of success it cannot enumerate.

(iii) SIPs get abandoned at the first regime change. An SIP is a contract with an unknown future. When the unknown briefly turns visible — a 20% drawdown, an inflation shock, a war — the ambiguity becomes intolerable. The SIP is paused, not because the math has changed, but because the felt ambiguity has spiked.

3. The Indian Manifestation — Where Ambiguity Aversion Costs Real Money

India offers an exceptionally clean laboratory for observing ambiguity aversion at scale, because the regulatory data is exceptionally good. Three specific datasets converge on the same diagnosis.

(a) The SEBI 2024 F&O loss study. SEBI’s expanded study, covering FY22, FY23 and FY24, reported that 9 out of 10 individual traders in the equity Futures & Options segment incurred net losses; aggregate retail losses across the period were of the order of ₹1.81 lakh crore. The same study showed that the median loss-making trader was a graduate, employed, in a metro, with a demat account less than three years old — the demographic least suffering from a literacy deficit. What they did suffer from was a profound preference for the false-precision of an option premium (a number on a screen) over the honest ambiguity of a 10-year equity hold. The Black-Scholes-implied probability felt knowable; the 10-year compounding distribution felt unknowable. Ellsberg’s urn-paradox, played out at industrial scale.

(b) The NSE 2024 cash-segment turnover data. NSE’s investor surveys consistently show that the median Indian equity holding period in the cash segment is under 5 months. For a population that overwhelmingly reports investing “for long-term wealth creation” in attitudinal surveys, this is a stark behaviour-attitude gap. The mechanism is ambiguity aversion: long horizons widen the probability cone, and the widening cone is intolerable.

(c) The AMFI SIP discontinuation data. AMFI’s monthly disclosures over CY2024 and CY2025 record SIP stoppage ratios oscillating between 70% and 110% (i.e. for every 100 SIPs registered, 70–110 were stopped or matured in the same month). The median age of a stopped SIP, per industry estimates, is between 18 and 24 months — nowhere near the holding period at which equity SIPs become tax-efficient or genuinely productive. The mechanism is not financial distress; it is ambiguity intolerance. The investor cannot bear a multi-year stretch of not-knowing-where-this-will-end.

The Indian academic literature has begun documenting this directly. Prof. V. Ravi Anshuman’s 2018 paper at IIM Bangalore (“Behavioral Biases in the Indian Equity Market”) reports that ambiguity-aversion measures, drawn from controlled urn experiments adapted for Indian retail participants, correlate strongly with portfolio concentration in BSE-100 names and with reluctance to allocate to small-cap and overseas funds. Meir Statman’s long body of cross-cultural work, translated to Indian respondents in collaborations with NSE Investor Protection Fund, finds Indian retail to be among the most ambiguity-averse cohorts globally, exceeding US and Continental European samples.

4. The Counter-Measure Checklist — How a Long-Term Investor Disarms Ambiguity Aversion

Ambiguity cannot be wished away; it is the underlying truth of investing in any forward-looking market. What CAN be done is two-fold: insist on companies that compress ambiguity through disclosure, and insist on a personal process that prices ambiguity rather than fleeing from it.

(i) Demand a multi-year audited history before allocating. Three to five years of audited consolidated financials, with consistent accounting policies, narrows the probability cone meaningfully. Single-year results are an Ellsberg urn.

(ii) Demand segment disclosure. A company that reports domestic vs. overseas, product vs. service, B2B vs. B2C revenue in numeric terms collapses ambiguity. A company that lumps everything into one segment forces you to bet on the unknown urn.

(iii) Demand explicit contingent-liability and related-party-transaction tables. These are the off-balance-sheet ambiguity sources. A precise rupee number with year-on-year change is anti-Ellsberg; a vague footnote is Ellsberg’s unknown urn.

(iv) Demand a stated capital-allocation policy. Dividend policy, capex policy, debt policy — written, dated, audited — converts the management’s future actions from a unknown-probability draw into a known-probability draw.

(v) Use base rates from the outside view. Kahneman and Lovallo’s reference-class forecasting is, in operational terms, an ambiguity-collapse tool: it replaces “I don’t know what this stock will do” with “in this reference class, the historical distribution is X.” You have moved from Urn B to Urn A.

(vi) Quantify what you can; flag what you can’t. Never let an ambiguous variable hide. List the unknowns explicitly in your decision journal. The act of writing “I do not know X” converts ambiguity into known risk — which the brain processes far more calmly.

(vii) Cap concentration when ambiguity is high. If five questions are unanswered, your position size should be one-fifth of what it would be with five questions answered. Position sizing is the cheapest ambiguity insurance available.

5. How the Masters Addressed Ambiguity Aversion

Benjamin Graham built his entire margin-of-safety doctrine on the assumption that ambiguity is permanent and must be priced. His famous formulation in The Intelligent Investor (1949) — that price is the only thing you can know with certainty and value is always an estimate — is Ellsberg avant la lettre. The margin of safety is the explicit ambiguity premium one demands before committing capital.

Warren Buffett generalised the principle in his 1996 letter on “The Inevitables.” A small handful of businesses, he wrote, have outcomes so narrowly distributed across foreseeable scenarios that ambiguity is materially compressed — you can predict their dominance with high confidence. Most businesses are not inevitables; they are highly probables (wider ambiguity) or hopefuls (Ellsberg’s unknown urn). Buffett does not deny ambiguity; he sizes his commitments by it.

Charlie Munger deployed the “too-hard pile” as his explicit ambiguity-management tool. A stock whose key variables are unknowable goes to the too-hard pile. He famously said that great investing comes from a relatively small number of decisions made when ambiguity is unusually low — the “fat pitch” principle, also attributed to Ted Williams. The patience to wait for ambiguity to collapse is, in Munger’s reading, the central investing skill.

Seth Klarman wrote in Margin of Safety (1991, out of print) that “value investing is risk-averse by nature.” In Ellsberg terms, value investors prefer Urn A — but unlike retail investors, they wait patiently until they can re-classify Urn B as Urn A through diligent research. This is the value investor’s edge over the algorithmic short-term trader: time horizon is the friend of ambiguity reduction.

6. Illustrative Case — How Titan Biotech Ltd (BSE: 524717) Exhibits Ambiguity-Collapse in Corporate Behaviour

This section is presented strictly as an educational case study of how a publicly listed Indian company’s disclosure and capital-allocation behaviour can be read against the lens of the Ellsberg 1961 paradox. It is NOT a valuation call, price target, buy/sell/hold recommendation, or investment advice. Investors must consult their SEBI-registered investment advisor and conduct independent due diligence.

Recall Ellsberg’s urns: Urn A has known probabilities; Urn B has unknown probabilities. From an investor’s vantage, every listed company is, in raw form, closer to Urn B — the future is unknown. The question is the extent to which the company’s management voluntarily moves itself toward Urn A through the quality and granularity of its disclosures. Titan Biotech Ltd’s FY25 annual report and ongoing communications provide a workable positive illustration of this ambiguity-collapse process. The audited consolidated numbers below are drawn from the FY25 annual report and Screener.in compilations.

The Ambiguity-Compression Markers

Read together, these nine markers describe a corporate disclosure architecture that systematically collapses ambiguity for the patient long-term investor. None of this is a comment on what the stock is worth on a given day, what its forward price will be, or what an appropriate allocation looks like — all of those questions remain, and must be resolved by the investor with their advisor. The point is that Titan Biotech’s behaviour as a discloser moves the analytical problem from Urn B toward Urn A, which is the precise corporate behaviour Ellsberg’s paradox tells us investors will reward over long horizons.

The contrast with the typical Indian small-cap is instructive. The median Indian small-cap by SEBI’s 2024 disclosure-quality survey provides:

• One-line segment reporting (or none).
• Aggregated contingent-liability footnotes without rupee precision.
• No three-year cash-conversion trail.
• Board meeting count not benchmarked against required minima.
• No 10-year audited compounding tables.

For an investor evaluating that median small-cap, every analytical question lands in Urn B. The ambiguity premium — in raw expected-return terms — that the investor must demand for that company is therefore much higher. Titan Biotech’s nine markers, by contrast, are how a small-cap can shrink that premium without changing its business at all — purely through disclosure architecture.

7. Key Takeaways

• Ambiguity aversion is not risk aversion. Ellsberg (1961) showed humans pay an excess premium specifically to avoid unknown probabilities. This is the bias behind ₹1.81 lakh crore of Indian F&O losses (SEBI 2024): retail traders prefer the false-precision of an option Greek over the honest uncertainty of a 10-year equity hold.
• SIP abandonment at month 21 is ambiguity-aversion in slow motion. The investor does not face new financial constraints — the felt ambiguity simply becomes intolerable. The cure is to pre-commit and pre-write the conditions under which an SIP would be reviewed.
• Diversification is not surrender; it is rational ambiguity insurance. The compulsion to concentrate in “known” names is the Ellsberg paradox at the portfolio level.
• Titan Biotech’s FY25 disclosure architecture — segment break-up (₹10,254.80 lakh domestic + ₹5,390.28 lakh overseas), three-year CFO/OP trail (103%/85%/97%), 81% debt reduction since FY21 (₹16 Cr → ₹3 Cr), 39.7% YoY drop in contingent liabilities, 14 board meetings, 36.4% independent directors and a 10-year 29% profit CAGR — is a textbook illustration of how a small-cap can systematically compress ambiguity for long-term investors. None of this is a valuation verdict; it is a process verdict.
• The masters all share one habit: they price ambiguity, they do not flee from it. Graham’s margin of safety, Buffett’s inevitables, Munger’s too-hard pile and Klarman’s risk-averse posture are four flavours of the same Ellsberg-aware discipline.
• The cure for ambiguity aversion at the portfolio level is process, not stories. A written investment policy, a quantified watchlist, base-rate-aware position sizing, and a decision journal collectively re-engineer the decision-architecture so that ambiguity is acknowledged and priced rather than denied.

Disclaimer: This article is for educational and informational purposes only. It is not investment advice, and not a buy, sell, or hold recommendation on any stock mentioned, including Titan Biotech Limited. Equity markets carry risk; please do your own research or consult a qualified professional before making investment decisions.

Manish Goel

Manish Goel is a long-term value investor and the founder of Manish Goel Stocks, where he publishes daily, plain-English lessons on fundamental analysis for Indian investors. His writing focuses on reading annual reports, decoding financial ratios, spotting red flags, and building the patience and discipline that compounding rewards. Every article here is educational — never a buy or sell call — and free to read.

See Full Bio